Identifying Potential Candidates for CAR T-Cell Therapy

Opinion
Video

A panel of experts on multiple myeloma introduce themselves and discuss the initial process of identifying patients who are potential candidates for CAR T-cell therapy.

  1. Could you describe the initial process of identifying and referring potential candidates for CAR T-cell therapy from the community setting to an academic center?
    1. What patient specific factors might you consider?
    2. Are there any criteria that patients need to meet in order to be ready to move to a community setting?Does this vary between community settings?
  2. What are some challenges you are seeing when transitioning from community to academic settings?
Recent Videos
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
4 experts in this video
4 experts in this video
Related Content